Clinical Takeaway
In this small pilot trial, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time by approximately 25 minutes in adults with diagnosed insomnia disorder, suggesting that at least acutely, this cannabinoid combination did not improve and may have worsened objective sleep duration. These findings highlight that patient-reported improvements with cannabinoids may not align with measurable changes in sleep architecture, and next-day alertness effects remain an important clinical consideration. Larger controlled trials are needed before cannabinoids can be routinely recommended as evidence-based sleep aids for insomnia.
#13 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
What This Study Teaches Us
A single dose of 10 mg THC plus 200 mg CBD reduced total sleep time by about 25 minutes and suppressed REM sleep by roughly 34 minutes in people with insomnia, with the REM suppression effect being quite pronounced. Despite these objective changes, next-day alertness and cognitive performance remained intact, though patients reported slightly more sleepiness the morning after.
Why This Matters Clinically
Clinicians prescribing cannabinoids for insomnia often assume they simply improve sleep, but this trial shows the actual mechanism is more complex: THC appears to shorten and alter sleep architecture rather than deepen it. Understanding that REM suppression occurs (a pattern similar to some older sedatives) matters for counseling patients and weighing long-term safety, especially since chronic REM loss has implications we don’t fully understand.
Study Snapshot
| Study Design | Pilot randomized controlled trial with crossover design (implied), double-blind |
| Population | 20 adults with DSM-5 insomnia disorder, 16 female, mean age 46 years |
| Intervention | Single oral dose of 10 mg THC and 200 mg CBD versus placebo |
| Primary Outcome | Objective sleep architecture (total sleep time, REM sleep, wake after sleep onset) and next-day alertness measured by 256-channel high-density EEG |
| Key Result | THC/CBD decreased total sleep time by 24.5 minutes and REM sleep by 33.9 minutes compared to placebo, with no meaningful next-day cognitive impairment but increased self-reported sleepiness |
Where This Paper Deserves Skepticism
This is a pilot study with only 20 subjects and a single acute dose, so we cannot generalize to chronic use or identify which component (THC or CBD) drove the effects. The CBD dose of 200 mg is quite high and not typical of many formulations, making real-world applicability unclear. The abstract does not specify funding source, blinding methods in detail, or whether washout periods were adequate, and the next-day window (9+ hours) may be too short to detect delayed impairment from the THC. Most importantly, we lack any long-term safety data on repeated REM suppression, which historically has raised concerns with other medications.
Dr. Caplan’s Take
I find this study genuinely useful for tempering expectations around cannabis and sleep. Patients come to me wanting to sleep longer and better, and the data here suggests THC/CBD may do neither on the sleep duration front. What intrigues me more is the REM suppression: it’s a real effect, measurable on EEG, and it mirrors what we saw with older barbiturates and some benzodiazepines. The next-day function appears preserved in this acute setting, which is reassuring, but I’m cautious about extrapolating to nightly use. I tell patients we simply don’t have the long-term human data yet to know if chronic REM loss from cannabis is benign or problematic.
Clinical Bottom Line
Oral THC/CBD shortened sleep and suppressed REM in this small acute trial without obvious next-day cognitive harm, but clinicians should not assume it’s a simple sleep aid and should counsel patients about the REM suppression effect and lack of long-term safety data for chronic use.
| |
Have thoughts on this? Share it:
